PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsGene therapy breakthrough for blood-clotting disease

BioNews

Gene therapy breakthrough for blood-clotting disease

Published 23 January 2013 posted in News and appears in BioNews 638

Author

Zara Mahmoud

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Scientists have successfully used gene therapy to alleviate the symptoms of the blood disease haemophilia B in six human volunteers, raising hope for a potential cure. The study has been hailed as a landmark trial for gene therapy...

Scientists have successfully used gene therapy to alleviate the symptoms of the blood disease haemophilia B in six human volunteers, raising hope for a potential cure.

The study, published in the New England Journal of Medicine (NEJM), is the result of a collaboration between researchers at St Jude Children's Research Hospital in Memphis, USA, and clinicians led by Dr Amit Nathwani at University College London. It has been hailed as a landmark trial as gene therapy has been plagued with unsuccessful clinical outcomes over its 20 year history.

Gene therapy specialist Dr Katherine High of Children's Hospital of Philadelphia, told the New York Times: 'I think it's incredibly exciting, and I say that even though these people are my competitors'. Dr High is in fact listed as a co-author of the paper due to monitoring work performed in her laboratory.

Haemophilia B is an inherited clotting disorder, linked to a defective gene on the X chromosome. The condition is most often found in men as women have two copies of the X chromosome, and are likely to inherit at least one 'correct' copy of the gene.

The disease manifests itself as the inability to produce clotting factor IX (FIX), a key protein in the formation of blood clots. Patients with haemophilia B suffer from spontaneous bleeding episodes and may require weekly infusions of FIX to live normal lives.

In the NEJM study, scientists transferred a working copy of the gene for FIX using a virus to carry it into cells. This carrier, an 'adenoviral vector', is often used in gene therapy to introduce genes into the body. However, the technique has often led to rejection of the carrier or destruction of the viral cells by the body's immune system.

But the researchers made several improvements to the technique. First, they optimised the gene sequence of the FIX gene, to maximise its effectiveness in human cells. Secondly, they used an adenovirus, AAV8, which usually infects monkeys, as the basis for their carrier. It was considered unlikely that AAV8 would provoke a strong immune response in humans. Once inside the body AAV8 targets liver cells: ideal for this study, as the liver normally produces FIX protein.

At the start of the study, the FIX levels in the blood of all six patients were less than one percent of normal levels. On treatment this rose in all patients and those receiving the highest doses saw their FIX levels rise to between seven and 11 percent of the normal amount.

All patients were less likely to suffer spontaneous internal bleeding, and most were able to increase the period between FIX infusions. In patients receiving gene therapy at low and intermediate doses, FIX levels stabilised to between two and three percent of normal, indicating that the FIX protein was now being made by patients' own liver cells.

'Even modest increases that raise FIX production to more than one percent of normal levels have the potential to dramatically affect a patient's quality of life and reduce bleeding episodes', said Dr Andrew Davidoff, chair of the St Jude Department of Surgery.

Dr Edward Tuddenham, director of the Haemophilia Centre at the Royal Free Hospital in London and a co-author on the study, told the New York Times: 'We are pretty close to the sweet spot. If all goes well, a genetic treatment for haemophilia B could be available for widespread use in a couple of years'.

Experts in the field were cautiously optimistic. Liver cells are able to regenerate and it is likely that the patients will need to be re-administered the FIX gene, increasing the risk of immune rejection. The patients also have a slightly higher risk of liver cancer and will be monitored accordingly.

Dr Ron Crystal, chairman of genetic medicine at Weill Cornell Medical College, who was not involved in the study, said: 'I think this is a terrific advance for the field. It's a good lesson in terms of don't give up on good ideas'.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
26 February 2018 • 2 minutes read

Gene therapy shows 'mind-blowing' success in treating haemophilia A

by Dr Sam Sherratt

A new gene therapy for haemophilia A has exceeded expectations in a recent clinical trial...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
11 December 2017 • 2 minutes read

Gene therapy hope for haemophilia

by Charlotte Spicer

Scientists have successfully used gene therapy to prevent bleeding in a small trial of patients with the inherited blood disorder haemophilia B...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
30 January 2015 • 2 minutes read

Biogen makes moves in gene therapy

by Dr Lucy Freem

Biogen Idec has made an investment deal to develop gene therapy treatments for haemophilia A and B....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
12 December 2014 • 2 minutes read

Pfizer to set up dedicated gene therapy development unit

by Seán Byrne

Pfizer has entered into a deal with biotech company Spark Therapeutics to conduct research into gene therapy for haemophilia B...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
20 June 2014 • 2 minutes read

Very small beta-thalassemia gene therapy trial gets investors' blood up

by Dr Anna Cauldwell

Two patients with the serious inherited blood disorder beta-thalassemia have been able to stop blood transfusions 12 days after receiving experimental gene therapy...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
17 January 2013 • 2 minutes read

Innovative gene therapy protects mice from HIV infection

by Dr Tamara Hirsch

US scientists have induced long-lasting HIV protection in mice from a single injection. Their study, published in the journal Nature, uses gene therapy to stimulate production of antibodies against the virus...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
15 November 2012 • 2 minutes read

Gene editing success for haemophilia

by Dr Caroline Hirst

Scientists have, for the first time, successfully treated a blood disorder by repairing errors in the DNA of a living animal. Researchers from The Children’s Hospital of Philadelphia, together with California-based Sangamo BioSciences, have applied an innovative genome editing technique to treat haemophilia B, which affects around one in 30,000 boys and men...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
16 October 2009 • 2 minutes read

Royal blood disorder identified

by Dr Antony Starza-Allen

Scientists have discovered that the so-called 'Royal disease' that afflicted Queen Victoria's descendants was a very rare form of haemophilia. By analysing the degraded DNA taken from the bones of what are believed to be the last children of Russian Tsar, Nicholas II, scientists at the University of Massachusetts, US, discovered a mutation occurring in F9 on the X chromosome responsible for the production of Factor IX, a clotting agent. A ma...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« US politician against gay marriage allegedly donated sperm to lesbian couples

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

6 July 2022 • 1 minute read

Frozen embryo transfers linked to high blood pressure in pregnancy

5 July 2022 • 1 minute read

Anorexia in pregnancy linked to increased risk of complications

5 July 2022 • 2 minutes read

Pregnancy after breast cancer treatment does not increase risk of recurrence

5 July 2022 • 1 minute read

No difference between fresh and frozen sperm for IUI

4 July 2022 • 2 minutes read

Shorter IVF protocol reduces risk of OHSS

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856